Phase
Condition
Cancer
Lactose Intolerance
Colic
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
DISEASE CHARACTERISTICS: Histologically confirmed pelvic cancer Planned therapy is to undergo continuous definitive or adjuvant external beam pelvic radiation therapy with or without fluorouracil (5-FU) plus or minus levamisole No split course radiation therapy Planned course of radiation therapy must also meet the following criteria: - Entire pelvis must be encompassed by the planned radiotherapy fields - Total planned dose to the central axis midplane or isocenter for the whole pelvic field must be between 4500-5350 cGy - Treatment must be given 4-5 times per week on a one-treatment-per-day basis No stool incontinence or stool frequency of 7 or more per day prior to initiation of radiation therapy Must be entered on study before the second radiation therapy fraction No current or prior metastases beyond pelvic regional lymph nodes Must have functioning rectum No planned perineal irradiation No anal cancer No active intraluminal gastrointestinal (GI) tumors Patients with completely resectioned GI tumors who also receive adjuvant treatment are eligible
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine less than 2 times upper limit of normal Other: No known allergy to glutamine No history of inflammatory bowel disease No other medical condition that may interfere with treatment Not pregnant or nursing Adequate contraception is required of all fertile patients
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent leucovorin or other chemotherapy agents, except 5-FU with or without levamisole Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics No prior pelvic radiotherapy No brachytherapy prior to completion of all external beam radiotherapy Surgery: No abdominal-perineal resection, Hartmann procedure, or other surgical procedure that has left patient without a functioning rectum
Study Design
Study Description
Connect with a study center
Saskatchewan Cancer Agency
Regina, Saskatchewan S4S 6X3
CanadaSite Not Available
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona 85259-5404
United StatesSite Not Available
CCOP - Illinois Oncology Research Association
Peoria, Illinois 61602
United StatesSite Not Available
CCOP - Carle Cancer Center
Urbana, Illinois 61801
United StatesSite Not Available
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa 52403-1206
United StatesSite Not Available
CCOP - Iowa Oncology Research Association
Des Moines, Iowa 10309-1016
United StatesSite Not Available
Siouxland Hematology-Oncology
Sioux City, Iowa 51101-1733
United StatesSite Not Available
CCOP - Wichita
Wichita, Kansas 67214-3882
United StatesSite Not Available
CCOP - Ann Arbor Regional
Ann Arbor, Michigan 48106
United StatesSite Not Available
CCOP - Duluth
Duluth, Minnesota 55805
United StatesSite Not Available
Mayo Clinic Cancer Center
Rochester, Minnesota 55905
United StatesSite Not Available
CentraCare Clinic
Saint Cloud, Minnesota 56303
United StatesSite Not Available
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska 68131
United StatesSite Not Available
Quain & Ramstad Clinic, P.C.
Bismarck, North Dakota 58501
United StatesSite Not Available
CCOP - Merit Care Hospital
Fargo, North Dakota 58122
United StatesSite Not Available
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio 43623-3456
United StatesSite Not Available
CCOP - Geisinger Clinical and Medical Center
Danville, Pennsylvania 17822-2001
United StatesSite Not Available
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota 57105-1080
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.